This is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.
Rufinamide up to 45 milligram per kilogram per day (mg/kg/day).
Inclusion Criteria: - Participants who were on rufinamide treatment and have completed Study E2080-G000-303 in Poland.
Exclusion Criteria: - Participants were randomized to the other antiepileptic drug (AED) treatment group in study E2080-G000-303.
Eisai Medical Information